Page last updated: 2024-10-23

aspirin and Child Behavior Disorders

aspirin has been researched along with Child Behavior Disorders in 3 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Child Behavior Disorders: Disturbances considered to be pathological based on age and stage appropriateness, e.g., conduct disturbances and anaclitic depression. This concept does not include psychoneuroses, psychoses, or personality disorders with fixed patterns.

Research Excerpts

ExcerptRelevanceReference
"Low-dose aspirin (LDA) given during pregnancy may alter brain development in very preterm infants."3.76Prenatal low-dose aspirin and neurobehavioral outcomes of children born very preterm. ( Ancel, PY; Arnaud, C; Fresson, J; Kaminski, M; Larroque, B; Marchand, L; Marret, S; Rozé, JC; Thirez, G; Truffert, P, 2010)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Marret, S1
Marchand, L1
Kaminski, M1
Larroque, B1
Arnaud, C1
Truffert, P1
Thirez, G1
Fresson, J1
Rozé, JC1
Ancel, PY1
de Jong, PC1
Zielhuis, GA1
Gabreëls, F1
Cohen, SN1
Cohen, JL1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680]11,976 participants (Actual)Interventional2016-03-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)

- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm189
Placebo Arm230

Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g

- Birth weight <2500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm1078
Placebo Arm1153

Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g

- Birth weight <1500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm78
Placebo Arm101

Fetal Outcome 4 - Incidence of Fetal Loss

- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm303
Placebo Arm353

Fetal Outcome 5 - Incidence of Spontaneous Abortion

- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm134
Placebo Arm152

Fetal Outcome 6 - Incidence of All Stillbirth

- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm141
Placebo Arm166

Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy

- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm42
Placebo Arm30

Incidence of Hypertensive Disorders of Pregnancy

- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)

InterventionParticipants (Count of Participants)
Intervention Arm352
Placebo Arm325

Incidence of Perinatal Mortality

- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm264
Placebo Arm309

Incidence of Preterm Birth

The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm668
Placebo Arm754

Incidence of Small for Gestational Age (SGA)

- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm1506
Placebo Arm1564

Maternal Outcome 1 - Incidence of Vaginal Bleeding

- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm214
Placebo Arm246

Maternal Outcome 2 - Incidence of Antepartum Hemorrhage

- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm26
Placebo Arm25

Maternal Outcome 3 - Incidence of Postpartum Hemorrhage

- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm54
Placebo Arm43

Maternal Outcome 4 - Incidence of Maternal Mortality

- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm9
Placebo Arm12

Maternal Outcome 5 - Incidence of Late Abortion

- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm23
Placebo Arm30

Maternal Outcome 6 - Change in Maternal Hemoglobin

Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.

InterventionParticipants (Count of Participants)
Intervention Arm290
Placebo Arm333

Maternal Outcome 7 - Incidence of Preterm, Preeclampsia

Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm8
Placebo Arm21

Other Studies

3 other studies available for aspirin and Child Behavior Disorders

ArticleYear
Prenatal low-dose aspirin and neurobehavioral outcomes of children born very preterm.
    Pediatrics, 2010, Volume: 125, Issue:1

    Topics: Aspirin; Cerebral Palsy; Child Behavior Disorders; Child, Preschool; Cohort Studies; Confidence Inte

2010
[Aspirin and pregnancy].
    Nederlands tijdschrift voor geneeskunde, 1990, Sep-08, Volume: 134, Issue:36

    Topics: Adolescent; Aspirin; Child; Child Behavior Disorders; Female; Humans; Male; Pregnancy; Pregnancy Com

1990
Pharmacotherapeutics. Review and commentary.
    Pediatric clinics of North America, 1974, Volume: 21, Issue:1

    Topics: Acetaminophen; Acetanilides; Amphetamine; Ampicillin; Analgesics; Anti-Bacterial Agents; Aspirin; Ch

1974